An-Najah National University Hospital, Palestine
An-Najah National University is Palestine’s leading academic institution in medicine and health care. Since the inception of its Faculty of Medicine in 1999, the university has made tremendous achievements in the promotion of medical science and care for Palestinians—the latest of these achievements being the An-Najah National University Hospital in Nablus.
Nablus has a population of more than 340,000 and is the second-largest country in the West Bank. The city is central to all northern villages, making it a natural hub for medical services to over 1,000,000 inhabitants. With only 24 government hospitals in the West Bank and Gaza, the ratio between hospital beds and the total population is 1 to 1,000. Recognizing this huge disparity, An-Najah’s Faculty of Medicine and Health Sciences, began construction of NNUH jointly with the Ministry of Health in 2008, establishing Palestine’s first university hospital.
Zenyaku Kogyo Co. Ltd., Japan
Since its foundation in 1950, Zenyaku Kogyo has been committed to develop innovative pharmaceuticals based on its corporate philosophy- “We serve people through creation of efficacy.” To help people to maintain and improve their quality of life (QOL), Zenyaku has been actively providing information on the proper use of medication and on the steps people are to take to lead healthier lives.
Takara Bio Inc., Japan
Takara Bio Inc. began as the biomedical business unit of Takara Shuzo Co., Ltd. (now Takara Holdings Inc.).
Based on the Company’s mission – Contributing to the health of humankind through the development of revolutionary biotechnologies such as gene therapy – Takara Bio will focus on three business segments that utilize its core biotechnology and encourage broader expansion: the Bioindustry Business, the basis for stable earning providing research reagents, scientific instruments, and various contracted services to universities and companies around the world; the AgriBio Business, the segment being nurtured as the Company’s secondary profit-making business; the Gene Therapy Business, the segment that the Company views as the foundation for future growth developing and commercializing gene therapies for cancer and AIDS.